

## Special Issue

# Molecular Pathways and Their Clinical Implications in Ischemic Heart Disease and Heart Failure: From Pathophysiology to Therapeutic Strategies

### Message from the Guest Editors

This Special Issue of *Biomedicines* aims to explore the latest insights into the molecular characterization of IHD and HF, from pathophysiological mechanisms to novel therapeutic approaches. We welcome contributions that elucidate the role of inflammation, oxidative stress, mitochondrial dysfunction, and genetic/epigenetic modifications in the progression of IHD and HF. Studies on biomarkers, molecular imaging techniques, and innovative pharmacological or gene-based therapies are particularly encouraged. Additionally, research on personalized and precision medicine approaches for optimizing patient outcomes will be highly relevant. This Special Issue invites original research articles, reviews, and clinical studies that enhance our understanding of molecular pathways in IHD and HF and pave the way for future translational applications. By bridging the gap between basic science and clinical practice, we aim to foster the development of cutting-edge, patient-centered treatment strategies.

### Guest Editors

Dr. Panagiotis Stachteas

Second Cardiology Department, Medical School, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Dr. Efstratios Karagiannidis

1. Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

2. Department of Emergency Medicine, AHEPA University Hospital, 54636 Thessaloniki, Greece

### Deadline for manuscript submissions

31 January 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/246415](https://mdpi.com/si/246415)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).